Tagged with M

Switzerland Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer, or Breitling, made-in-Switzerland pharmaceuticals do not necessarily come cheap, but the country’s network of life science manufacturers seem content that…

Switzerland Switzerland is a highly decentralised nation where much of the decision-making power lies within individual Cantons and where the Federal presidency is rotated annually. To consistently keep industry interests on the national agenda against this backdrop, a dense network of well-resourced and highly sophisticated professional associations has evolved in Switzerland.…

Switzerland Switzerland’s healthcare system is globally renowned. It leads the world on metrics such as infrastructure, medical advances, and patient freedom to choose healthcare services, and ranks 1st in US thinktank FREOPP’s 2022 World Index of Healthcare Innovation. However, it lags in one key area: digitalisation. On that front, Switzerland has…

Switzerland Switzerland has a vital role to play in global health, especially in the world’s poorest countries. Indisputably the global capital for health and humanitarian work, its political neutrality, central European location, economic stability, and quality of life have helped foster a dense network of UN agencies, NGOs, and private sector…

Switzerland As home to much of Europe’s innovative medicine output and as one of its wealthiest nations per capita, Switzerland has not traditionally been a generic-friendly market. Generics prices are relatively high in a European context and only accounted for 14 percent of total drug sales in 2022. Nevertheless, in recent…

Switzerland Although the global biotech sector is currently struggling with equity and debt financing, Swiss biotech is on the up. 2023 saw the Swiss biotech sector hit record revenues of CHF 7.3 billion (EUR 7.8 billion) with capital investments surpassing CHF 2 billion. While funding inflows still did not reach the…

China Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, provides an in-depth analysis of the development of China’s healthcare landscape over the previous past four years. Ewert highlights key trends such as the growing role of local biopharma players, the impact of value-based pricing, and the changing…

Saudi Arabia This interview explores Bayer’s strategic initiatives across the Middle East and North Africa (MENA) region, highlighting its commitment to innovation, local talent development, and sustainability. Over the next few years, Bayer aims to enhance accessibility to groundbreaking healthcare solutions while deepening relationships with local and international stakeholders. As Hugo Hagen,…

China Jun Liu, CEO & Executive Board Director of BioDlink, defines and explores the company’s strategic focus on antibody drug conjugates (ADCs), their global expansion plans, and role as a leading CDMO. Liu emphasises the balance of quality and cost efficiency, stating, “Our mission is to deliver exceptional value, ensuring we…

China Vivian Zhang, Managing Director and General Manager of Merck China Healthcare, shares insights into the market’s strategic importance to the company and its current priorities in the country. She discusses Merck’s long-term commitment to China, highlighting the company’s 91 years of operations in the country, diverse portfolio, strong emphasis on…

Global IFPMA represents the innovative pharmaceutical industry at the international level and in official relations with the United Nations. Dr David Reddy joined the association earlier this year, and shares his analysis on how vaccines and treatments are transforming health outcomes for people around the world, and how the pipeline of…

China EpimAb Biotherapeutics’ Chengbin Wu explains why the expansion of bispecifics into solid tumors and autoimmune diseases marks a major therapeutic turning point. He outlines how, through rational antibody engineering and unique molecule formats, EpimAb has differentiated itself with safer, more effective therapies than its competitors, as well as how the…